Business
Enanta Pharmaceuticals Announces Data Presentations at the European Association for the Study of the Liver (EASL) Digital International Liver Congress™ 2020
WATERTOWN, Mass.--(BUSINESS WIRE)-- Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule
About this update from Enanta Pharmaceuticals, Inc.
[{"type":"text","content":" WATERTOWN, Mass.--(BUSINESS WIRE)--\nEnanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced that clinical data from Enanta’s wholly-owned development programs for non-alcoholic steatohepatitis (NASH) and hepatitis B virus (HBV) have been accepted for presentations at the European Association for the Study of the Liver (EASL) Digital International Liver Congress 2020 being held August 27-29, 2020. \n\n\nClinical data will include an oral presentation of the Phase 2a ARGON-1 study of EDP-305, Enanta’s Farnesoid X receptor (FXR) agonist for the treatment of NASH, as well as a poster on new Phase 1 data of EDP-514, Enanta’s core inhibitor for HBV. Preclinical data on EDP-297, Enanta’s follow-on FXR agonist for NASH, will also be highlighted in two poster presentations.\n\n\nThe full scientific program for The Digital International Liver Congress 2020, as well as the abstracts, can be found at https://ilc-congress.eu/programme-digital-ilc-2020/. Further details will be available at the time of these presentations.\n\n\nOral Presentation:\nAugust 28, 2020, 12:15 - 12:30 CEST\nAS078: “EDP-305, A Non-Bile Acid Farnesoid X Receptor (FXR) Agonist, Showed Statistically Significant Improvements in Liver Biochemistry and Hepatic Steatosis in the Phase 2a ARGON-1 Study”\nLocation: Channel 3\nPresenter: Vlad Ratziu, M.D., Ph.D., France\n\n\nPoster Presentations:\nAugust 28, 2020, 09:30 - 19:30 CEST\nFRI109: “EDP-297, A Novel and Potent FXR Agonist, Exhibits Robust Anti-Fibrotic Effects with Significant Liver Function Improvement in a Rat Model of Non-Alcoholic Steatohepatitis”\nPresenter: Mozhdeh Sojoodi, Ph.D., United States\n\n\nAugust 29, 2020, 09:30 - 19:30 CEST\nSAT042: “A Novel FXR Agonist EDP-297 Exerts Anti-Inflammatory and Hepatoprotective Effects in Human Liver 3D Microtissues and in Rodent Models of Liver Injury and NASH”\nPresenter: Mary Chau, Ph.D., United States\n\n\nAugust 29, 2020, 09:30 - 19:30 CEST\nSAT440: “EDP-514, a Novel Pangenotypic Class II Hepatitis B Virus Core Inhibitor: Final Results of a Phase 1 Study in Healthy Adult Subjects”\nPresenter: Kajal Larson, Ph.D., United States\n\n\nAbout Enanta\n\n\nEnanta is using its robust, chemistry-driven approach and drug discovery capabilities to beco...